Key Stats for Moderna Stock
- Price change for Moderna stock: 177%
- $MRNA Stock Price as of Aug. 19: $174
- 52-Week High: $177
- $MRNA Stock Price Target: $59
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Moderna (MRNA) stock exploded higher on Wednesday, jumping about 177% after Moderna and Merck announced positive results from their first-ever late-stage trial of a personalized cancer vaccine.
The shot, used alongside Merck’s immunotherapy Keytruda, hit its main goal in a Phase 3 study of more than 1,100 melanoma patients whose tumors had already been surgically removed.
The combination significantly extended how long patients went without their cancer returning, compared to Keytruda alone. It also cut the risk of the cancer spreading to other parts of the body. These results build on strong Phase 2 data shown earlier this year.
Moderna CEO Stéphane Bancel called it “a big moment for medicine, a big moment for patients” in a CNBC interview. Merck’s Dr. Dean Li said the companies plan to start talking with regulators about the treatment “in the next few months.”
The vaccine targets the specific mutations found in each patient’s tumor, rather than taking a one-size-fits-all approach.
It trains the immune system to recognize and attack those unique markers, while Keytruda helps the body fight the cancer more effectively. Merck’s Dr. Jane Healy called the improvement over Keytruda alone “clinically meaningful,” adding that side effects looked similar to other common vaccines.
See analysts’ growth forecasts and price targets for Moderna stock (It’s free) >>>
What the Market Is Telling Us About Moderna Stock
The huge jump in Moderna stock shows just how much was riding on this one trial.
Leerink Partners analyst Mani Foroohar had called the Phase 3 results a “make-or-break event” for Moderna stock ahead of the readout, and Wednesday’s move suggests investors agree the news landed firmly on the “make” side.
Part of the dramatic reaction comes down to size. Merck is a $333 billion company, so a positive melanoma readout is a nice win but a smaller piece of the overall picture. Moderna, at roughly $25 billion before the news, is far more dependent on pipeline breakthroughs like this one to drive its valuation higher.
The company enters this milestone in a stable financial position.
In its most recent quarter, Moderna held $6.9 billion in cash and investments and reiterated guidance for revenue to grow up to 10% in 2026, while also lowering its cost estimates for the year.
That financial cushion gives the company room to keep funding its cancer vaccine program, which is also being tested in lung, bladder, and kidney cancers.
For now, the market is treating this as validation of a personalized cancer vaccine approach that Moderna and Merck have spent years developing, and Moderna stock’s reaction reflects how significant investors think this data could be for the company’s future.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Moderna Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
